Immunosuppressive parameters in serum of ovarian cancer patients change during the disease course

OncoImmunology

Volumn 5, Issue 4, 2016, Pages

  Coosemans, An ^a,b   Decoene, Judit ^a   Baert, Thaïs ^a,b   Laenen, Annouschka ^c   Kasran, Ahmad ^c   Verschuere, Tina ^c   Seys, Sven ^c   Vergote, Ignace ^a,b  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b KU Leuven and University Hospitals Leuven and Leuven Cancer Institute   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Arginase; CCL 2; debulking; galectin 1; immunosuppression; ovarian cancer; paclitaxel carboplatin; VEGF

Indexed keywords

ARGINASE; CARBOPLATIN; GALECTIN 1; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4; MONOCYTE CHEMOTACTIC PROTEIN 1; PACLITAXEL; TRANSFORMING GROWTH FACTOR BETA; TREBANANIB; VASCULOTROPIN A;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ANGIOGENESIS; ARTICLE; BLOOD SAMPLING; CANCER GRADING; CANCER PATIENT; CANCER PROGNOSIS; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE COURSE; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNE DEFICIENCY; MAJOR CLINICAL STUDY; METABOLITE; MULTIPLE CYCLE TREATMENT; OVARY CANCER; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; T LYMPHOCYTE; TUMOR ESCAPE; UTERINE TUBE;

EID: 84962857583     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1111505     Document Type: Article

References (55)

1. R.Siegel, J.Ma, Z.Zou, A.Jemal. Cancer statistics, 2014. CA Cancer J Clin 2014; 64:9-29; PMID:24399786; http://dx.doi.org/10.3322/caac.21208
2. I.Vergote, C.G.Tropé, F.Amant, G.B.Kristensen, T.Ehlen, N.Johnson, R.H.Verheijen, M.E.van der Burg, A.J.Lacave, P.B.Panici et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010; 363:943-53; PMID:20818904; http://dx.doi.org/10.1056/NEJMoa0908806
3. G.Chene, J.Dauplat, N.Radosevic-Robin, A.Cayre, F.Penault-Llorca. Tu-be or not tu-be: that is the question…about serous ovarian cancer carcinogenesis. Crit Rev Oncol Hematol 2013; 88:134-43; PMID:23523591; http://dx.doi.org/10.1016/j.critrevonc.2013.03.004
4. R.D.Sorensen, T.H.Schnack, M.A.Karlsen, C.K.Hogdall. Serous ovarian, fallopian tube and primary peritoneal cancers: a common disease or separate entities – a systematic review. Gynecol Oncol 2015; 136:571-81; PMID:25615934; http://dx.doi.org/10.1016/j.ygyno.20-15.01.534
5. R.D.Schreiber, L.J.Old, M.J.Smyth. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011; 331:1565-70; PMID:21436444; http://dx.doi.org/10.1126/science.1203486
6. T.Baert, D.Timmerman, I.Vergote, A.Coosemans. Immunological parameters as a new lead in the diagnosis of ovarian cancer. Facts Views Vis Obgyn 2015; 1:67-72; PMID:25897373
7. T.F.Gajewski, H.Schreiber, Y.-X.Fu. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 2013; 14:1014-22; PMID:24048123; http://dx.doi.org/10.1038/ni.2703
8. S.Nagaraj, D.I.Gabrilovich. Myeloid-derived suppressor cells in human cancer. Cancer J 2010; 16:348-53; PMID:20693846; http://dx.doi.org/10.1097/PPO.0b013e3181eb3358
9. J.E.Talmadge, D.I.Gabrilovich. History of myeloid-derived suppressor cells. Nat Rev Cancer 2013; 13:739-52; PMID:24060865; http://dx.doi.org/10.1038/nrc3581
10. R.Noy, J.W.Pollard. Tumor-Associated Macrophages: From Mechanisms to Therapy. Immunity 2014; 41:49-61; PMID:25035953; http://dx.doi.org/10.1016/j.immuni.2014.06.010
11. G.A.Rabinovich, J.M.Ilarregui. Conveying glycan information into T cell homeostatic programs: a challenging role for galectin-1 in inflammatory and tumor microenvironments. Immunol Rev 2009; 230:144-59; PMID:19594634; http://dx.doi.org/10.1111/j.1600065X.2009.00787.x
12. K.Ito, K.Stannard, E.Gabutero, A.M.Clark, S.-Y.Neo, S.Onturk, H.Blanchard, S.J.Ralph. Galectin-1 as a potent target for cancer therapy: role in the tumor microenvironment. Cancer Metastasis Rev 2012; 31:763-78; PMID:22706847; http://dx.doi.org/10.1007/s10555-012-9388-2
13. D.O.Croci, J.P.Cerliani, T.Dalotto-Moreno, S.P.Méndez-Huergo, I.D.Mascanfroni, S.Dergan-Dylon, M.A.Toscano, J.J.Caramelo, J.J.Garcia-Vallejo, J.Ouyang et al. Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors. Cell 2014; 156:744-58; PMID:24529377; http://dx.doi.org/10.1016/j.cell.2014.01.043
14. P.Zhang, B.Shi, M.Zhou, H.Jiang, H.Zhang, X.Pan, H.Gao, H.Sun, Z.Li. Galectin-1 overexpression promotes progression and chemoresistance to cisplatin in epithelial ovarian cancer. Cell Death Dis 2014; 5:e991; PMID:24407244; http://dx.doi.org/10.1038/cddis.2013.526
15. T.Verschuere, M.Van Woensel, S.Fieuws, F.Lefranc, V.Mathieu, R.Kiss, S.W.Van Gool, S.De Vleeschouwer. Altered galectin-1 serum levels in patients diagnosed with high-grade glioma. J Neurooncol 2013; 115:9-17; PMID:23824536; http://dx.doi.org/10.1007/s11060-013-1201-8
16. C.Napoletano, F.Bellati, R.Landi, S.Pauselli, C.Marchetti, V.Visconti, P.Sale, M.Liberati, A.Rughetti, L.Frati et al. Ovarian cancer cytoreduction induces changes in T cell population subsets reducing immunosuppression. J Cell Mol Med 2010; 14:2748-59; PMID:19780872; http://dx.doi.org/10.1111/j.1582-4934.2009.00911.x
17. M.Nowak, E.Glowacka, M.Szpakowski, K.Szyllo, A.Malinowski, A.Kulig, H.Tchorzewski, J.Wilczynski. Proinflammatory and immunosuppressive serum, ascites and cyst fluid cytokines in patients with early and advanced ovarian cancer and benign ovarian tumors. Neuro Endocrinol Lett 2010; 31:375-83; PMID:20588232.
18. H.Nishio, T.Yaguchi, J.Sugiyama, H.Sumimoto, K.Umezawa, T.Iwata, N.Susumu, T.Fujii, N.Kawamura, A.Kobayashi et al. Immunosuppression through constitutively activated NF-κB signalling in human ovarian cancer and its reversal by an NF-κB inhibitor. Br J Cancer 2014; 110:2965-74; PMID:24867687; http://dx.doi.org/10.1038/bjc.2014.251
19. M.N.Svendsen, K.Werther, H.J.Nielsen, P.E.G.Kristjansen. VEGF and tumour angiogenesis. Impact of surgery, wound healing, inflammation and blood transfusion. Scand J Gastroenterol 2002; 37:373-9; PMID:11989825; http://dx.doi.org/10.1080/003655202317315971
20. E.Bandiera, R.Franceschini, C.Specchia, E.Bignotti, C.Trevisiol, M.Gion, S.Pecorelli, A.D.Santin, A.Ravaggi. Prognostic significance of vascular endothelial growth factor serum determination in women with ovarian cancer. ISRN Obstet Gynecol 2012; 2012:245756; PMID:22792477; http://dx.doi.org/10.5402/2012/245756
21. S.Mahner, L.Woelber, C.Eulenburg, J.Schwarz, W.Carney, F.Jaenicke, K.Milde-Langosch, V.Lueller. TIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patients. BMC Cancer 2010; 10:139; PMID:20388222; http://dx.doi.org/10.1186/1471-2407-10-139
22. C.Rudlowski, A.-K.Pickart, C.Fuhljahn, T.Friepoertner, B.Schlehe, S.Biesterfeld, W.Schroeder. Prognostic significance of vascular endothelial growth factor expression in ovarian cancer patients: a long-term follow-up. Int J Gynecol Cancer 2006; 16 Suppl 1:183-9; PMID:16515588; http://dx.doi.org/10.1111/j.1525-1438.2006.00307.x
23. L.Yu, L.Deng, J.Li, Y.Zhang, L.Hu. The prognostic value of vascular endothelial growth factor in ovarian cancer: a systematic review and meta-analysis. Gynecol Oncol 2013; 128:391-6; PMID:23142075; http://dx.doi.org/10.1016/j.ygyno.2012.11.002
24. M.Le Mercier, F.Lefranc, T.Mijatovic, O.Debeir, B.Haibe-Kains, G.Bontempi, C.Decaestecker, R.Kiss, V.Mathieu. Evidence of galectin-1 involvement in glioma chemoresistance. Toxicol Appl Pharmacol 2008; 229:172-83; PMID:18313712; http://dx.doi.org/10.1016/j.taap.2008.01.009
25. H.M.Strik, K.Schmidt, P.Lingor, L.Tönges, W.Kugler, M.Nitsche, G.A.Rabinovich, M.Bähr. Galectin-1 expression in human glioma cells: modulation by ionizing radiation and effects on tumor cell proliferation and migration. Oncol Rep 2007; 18:483-8; PMID:17611674; http://dx.doi.org/10.3892/or.18.2.483
26. H.-J.Kim, H.-K.Jeon, Y.J.Cho, Y.A.Park, J.-J.Choi, I.-G.Do, S.Y.Song, Y.Y.Lee, C.H.Choi, T.J.Kim et al. High galectin-1 expression correlates with poor prognosis and is involved in epithelial ovarian cancer proliferation and invasion. Eur J Cancer 2012; 48:1914-21; PMID:22386573; http://dx.doi.org/10.1016/j.ejca.2012.02.005
27. L.Y.Chung, S.J.Tang, G.H.Sun, T.Y.Chou, T.S.Yeh, S.L.Yu, K.H.Sun. Galectin-1 promotes lung cancer progression and chemoresistance by upregulating p38 MAPK, ERK, and cyclooxygenase-2. Clin Cancer Res 2012; 18:4037-47; PMID:22696230; http://dx.doi.org/10.1158/1078-0432.CCR-11-3348
28. J.O.Falcão-Júnior, A.Teixeira-Carvalho, E.B.Cândido, E.L.Lages, G.G.Ferreira Freitas, R.M.Lamaita, L.P.Freire Bonfim, R.Borges Salera, P.P.Traiman, A.L.da Silva-Filho. Assessment of chemokine serum levels in epithelial ovarian cancer patients. Tumori 2013; 99:540-4; PMID:24326845; http://dx.doi.org/10.1700/1361.15108
29. E.Gorelik, D.P.Landsittel, A.M.Marrangoni, F.Modugno, L.Velikokhatnaya, M.T.Winans, W.L.Bigbee, R.B.Herberman, A.E.Lokshin. Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer. Cancer Epidemiol Biomarkers Prev 2005; 14:981-7; PMID:15824174; http://dx.doi.org/10.1158/1055-9965.EPI-04-0404
30. L.Hefler, C.Tempfer, G.Heinze, K.Mayerhofer, G.Breitenecker, S.Leodolter, A.Reinthaller, C.Kainze. Monocyte chemoattractant protein-1 serum levels in ovarian cancer patients. Br J Cancer 1999; 81:855-9; PMID:10555758; http://dx.doi.org/10.1038/sj.bjc.6690776
31. M.Tsai-Turton, A.Santillan, D.Lu, R.E.Bristow, K.C.Chan, I.M.Shih, R.B.Roden. p53 autoantibodies, cytokine levels and ovarian carcinogenesis. Gynecol Oncol 2009; 114:12-7; PMID:19398128; http://dx.doi.org/10.1016/j.ygyno.2009.03.028
32. M.Li, D.A.Knight, L.A Snyder, M.J.Smyth, T.J.Stewart. A role for CCL2 in both tumor progression and immunosurveillance. Oncoimmunology 2013; 2:e25474; PMID:24073384; http://dx.doi.org/10.4161/onci.25474
33. H.W.Wang, J.A.Joyce. Alternative activation of tumor-associated macrophages by IL-4: Priming for protumoral functions. Cell Cycle 2010; 9:4824-35; PMID:21150330; http://dx.doi.org/10.4161/cc.9.24.14322
34. G.Landskron, M.De La Fuente, P.Thuwajit, C.Thuwajit, M.A.Hermoso. Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res 2014; 2014:149185; PMID:24901008; http://dx.doi.org/10.1155/2014/149185.
35. T.Fujisawa, B.H.Joshi, R.K.Puri. IL-13 regulates cancer invasion and metastasis through IL-13Rα2 via ERK/AP-1 pathway in mouse model of human ovarian cancer. Int J Cancer 2012; 131:344-56; PMID:21858811; http://dx.doi.org/10.1002/ijc.26366
36. X.Zhang, W.Weng, W.Xu, Y.Wang, W.Yu, X.Tang, L.Ma, Q.Pan, J.Wang, F.Sun. Prognostic significance of interleukin 17 in cancer: a meta-analysis. Int J Clin Exp Med 2014; 7:3258-69; PMID:25419357
37. F.Yao, S.Yan, X.Wang, D.Shi, J.Bai, F.Li, B.Sun, B.Qian. Role of IL-17F T7488C polymorphism in carcinogenesis: a meta-analysis. Tumor Biol 2014; 35:9061-8; PMID:24913709; http://dx.doi.org/10.1007/s13277-014-2171-y
38. C.Lan, X.Huang, S.Lin, H.Huang, Q.Cai, J.Lu, J.Liu. High density of IL-17-producing cells is associated with improved prognosis for advanced epithelial ovarian cancer. Cell Tissue Res 2013; 352:351-9; PMID:23397428; http://dx.doi.org/10.1007/s00441-013-1567-0
39. M.S.Block, M.J.Maurer, K.Goergen, K.R.Kalli, C.L.Erskine, M.D.Behrens, A.L.Oberg, K.L.Knutson. Plasma immune analytes in patients with epithelial ovarian cancer. Cytokine 2015; 73:108-13; PMID:25743245; http://dx.doi.org/10.1016/j.cyto.2015.01.035
40. P.C.Rodriguez, D.G.Quiceno, A.C.Ochoa. L-arginine availability regulates T-lymphocyte cell-cycle progression. Blood 2007; 109:1568-73; PMID:17023580; http://dx.doi.org/10.1182/blood-2006-06-031856
41. C.I.Chang, J.C.Liao, L.Kuo. Macrophage arginase promotos tumor cell growth and suppresses nitric-mediated tumur cytotoxicity. Cancer Res 2001; 61:1100-6; PMID:11221839
42. O.R.Colegio, N.Q.Chu, A.L.Szabo, T.Chu, A.M.Rhebergen, V.Jairam, N.Cyrus, C.E.Brokowski, S.C.Eisenbarth, G.M.Philips et al. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature 2014; 513:559-63; PMID:25043024; http://dx.doi.org/10.1038/nature13490
43. A.Casazza, D.Laoui, M.Wenes, S.Rizzolio, N.Bassani, M.Mambretti, S.Deschoemaeker, J.A.Van Ginderachter, L.Tamagnone, M.Mazzone. Impeding macrophage entry into hypoxic tumor areas by Sema3A/Nrp1 signaling blockade inhibits angiogenesis and restores antitumor immunity. Cancer Cell 2013; 24:695-709; PMID:24332039; http://dx.doi.org/10.1016/j.ccr.2013.11.007
44. R.Yigit, L.F.A.G.Massuger, C.G.Figdor, R.Torensma. Ovarian cancer creates a suppressive microenvironment to escape immune elimination. Gynecol Oncol 2010; 117:366-72; PMID:20144842; http://dx.doi.org/10.1016/j.ygyno.2010.01.019
45. B.F.Zamarron, W.Chen. Dual roles of immune cells and their factors in cancer development and progression. Int J Biol Sci 2011; 7:651-8; PMID:21647333; http://dx.doi.org/10.7150/ijbs.7.651
46. S.Komiyama, T.Kurahashi, M.Ishikawa, K.Tanaka, M.Komiyama, M.Mikami, Y.Udagawa. Expression of TGFβ1 and its receptors is associated with biological features of ovarian cancer and sensitivity to paclitaxel/carboplatin. Oncol Rep 2011; 25:1131-8; PMID:21249319; http://dx.doi.org/10.3892/or.2011.1151
47. F.Tas, S.Karabulut, M.Serilmez, R.Ciftci, D.Duranyildiz. Clinical significance of serum epithelial cell adhesion molecule (EPCAM) and vascular cell adhesion molecule-1 (VCAM-1) levels in patients with epithelial ovarian cancer. Tumor Biol 2013; 1:1-8; PMID:24307621; http://dx.doi.org/10.1007/s13277-013-1401-z
48. S.L.Deshmane, S.Kremlev, S.Amini, B.E.Sawaya. Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res 2009; 29:313-26; PMID:19441883; http://dx.doi.org/10.1089/jir.2008.0027
49. J.Zhang, L.Patel, K.J.Pienta. Targeting chemokine (C-C motif) Ligand 2 (CCL2) as an example of translation of cancer molecular biology to the clinic. Prog Mol Biol Transl Sci 2010; 95:31-53; PMID:21075328; http://dx.doi.org/10.1016/B978-0-12-385071-3.00003-4
50. M.A.Getter, T.M.Bui-Nguyen, L.M.Rogers, S.Ramakrishnan. Chemotherapy induces macrophage chemoattractant protein-1 production in ovarian cancer. Int J Gynecol Cancer 2010; 20:918-25; PMID:20683396; http://dx.doi.org/10.1111/IGC.0b013e3181e5c442
51. A.N.Fader, N.Rasool, S.A.J.Vaziri, T.Kozuki, P.W.Faber, P.Elson, C.V.Biscotti, C.M.Michener, P.G.Rose, L.Rojas-Espaillat et al. CCL2 expression in primary ovarian carcinoma is correlated with chemotherapy response and survival outcomes. Anticancer Res 2010; 30:4791-8; PMID:21187454
52. Z.Duan, A.J.Feller, R.T.Penson, B.A.Chabner, M.V.Seiden. Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: Analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein I in the paclitaxel-resistant phenotype. Clin Cancer Res 1999; 5:3445-53; PMID:10589757
53. H.L.Goel, A.M.Mercurio. VEGF targets the tumour cell. Nat Rev Cancer 2013; 13:871-82; PMID:24263190; http://dx.doi.org/10.1038/nrc3627
54. R.K.Jain. Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell 2014; 26:605-22; PMID:25517747; http://dx.doi.org/10.1016/j.ccell.2014.10.006
55. S.R.Kandukuri, J.Rao. FIGO 2013 staging system for ovarian cancer: what is new in comparison to 1988 staging system? Curr Opin Obstet Gynecol 2015; 27:48-52; PMID:25490382; http://dx.doi.org/10.1097/GCO.0000000000000135